Not yet recruiting NCT07339358

Safety & Performance of the World Medica World Diverter Embolization Device

No phase Interventional Intracranial Aneurysm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied: The protocol lists: Flow diverter implantation.
Who it may be relevant to: Registry conditions: Intracranial Aneurysm. Basic parameters: 22 years — 80 years · All.
What needs checking: Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place: Spain
Next step: Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The objective of this study is to investgiate the safety and clinical performance of the World Diverter Emoblization Device for the endovascular treatment of wide-neck (neck width ≥ 4 mm or dome-to-neck ratio \<2) or fusiform intracranial aneurysms in the internal carotid artery (ICA) from the petrous segment to the terminus arising from a parent vessel with a diameter ≥ 2.5 mm and ≤ 5.5 mm.

Interventions

Device Flow diverter implantation
Implantation of the World Diverter Embolization Device

Primary outcome measures

Primary Safety - Major Adverse Events (MAEs) [Time frame: 12 months]
Primary Effectiveness - Complete Occlusion [Time frame: 12 months]

Secondary outcome measures (7)

Medium-Term Effectiveness [Time frame: 6 months]
Medium-Term Parent Artery Stenosis [Time frame: 6 months]
Medium-Term Functional Outcomes [Time frame: 6 months]
Secondary Effectiveness - Adequate Occlusion [Time frame: 12 months]
Long-Term Angiographic Outcome [Time frame: 12 months]
Long-Term Parent Artery Stenosis [Time frame: 12 months]
Long-Term Functional Outcome [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

Age 18 22 to 80 years
Subject, or subject's legal representative provided informed consent
Subject agrees to the requirements of the study, including returning for required follow-up visits
Parent artery diameter of 2.0-5.5 mm distal and proximal to the target IA
Subject has a single target IA in the index procedure with the following characteristics: (1) Unruptured; (2) Located in the ICA from the petrous through the superior hypophyseal segments; and (3) Is a fusiform or saccular wide-necked IA with one of the following characteristics: (a) Small (< 5 mm) or medium (>5-10 mm) size with a neck width ≥ 4.0 mm or a dome-to-neck ratio of < 2; OR (b) Large (>10-25 mm) or giant (>25 mm) size

Exclusion criteria

A subarachnoid or intracerebral hemorrhage in the 60 days preceding the index procedure
A bleeding disorder or a platelet count of less than 100x103/mm3 or INR >1.5
A contraindication to or inability to tolerate antiplatelet therapy
An allergy to radiographic contrast agents
An allergy to nickel, titanium, platinum, tungsten, or stainless steel
An allergy to local or general anesthesia
A history of untreated atrial fibrillation, untreated/uncontrollable hypertension, or other stroke risk factors
A history of deep vein thrombosis or pulmonary embolism
A history of heart failure, dilated cardiomyopathy, or congenital heart conditions
Hypercoagulopathy or a hemorrhagic or coagulation deficiency refractory to medical therapy or subject refuses treatment with blood products
Suffered a stroke within 180 days preceding the index procedure
Had major surgery within the 30 days preceding or planned for the 180 days following the index procedure, including but not limited to intracranial stenting or coiling
Target aneurysm has been previously treated with clipping, coiling, or flow diversion
Had previous stenting of or implant in parent artery proximal to the target aneurysm that could interfere with delivery or performance of study device
Asymptomatic extradural aneurysms requiring treatment
Contraindication to computed tomography (CT) or magnetic resonance (MR)
An unstable neurological deficit (i.e., worsening of a clinical condition within the 30 days preceding the index procedure)
Evidence of an active systemic infection (including COVID-19) at index procedure
Dementia or other cognitive condition limiting their ability to participate in the study
A condition that may limit survival to less than 12 months post-index procedure
Serum creatinine ≥2.5 mg/dL
Had radiation or chemotherapy treatment either currently or within the 60 days preceding the index procedure
Current enrollment in a separate clinical trial
Another condition(s) that, in the opinion of the Investigator, could interfere with the ability to perform a safe or effective procedure
Current pregnancy or plan to become pregnant within the 12 months following the index procedure, or be currently breastfeeding

Angiographic Exclusion Criteria:

Anatomy not amenable to endovascular treatment, including but not limited to severe vessel tortuosity or stenosis
Parent vessel stenosis is >50% in the target area
Extracranial stenosis of the carotid artery >50%
An intracranial mass
More than one vessel segment requiring IA treatment in the 12 months following the index procedure
Target aneurysm is mycotic or dissecting
Target aneurysm is at bifurcation
Target aneurysm will require coiling in addition to flow diversion, in Investigator's opinion

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation: N/A
Model: Single group
Masking: Open label
Primary purpose: Treatment

Study locations

Spain · 1 center

Hospital Universitari Vall d'Hebron — Barcelona

Identifiers

NCT: NCT07339358 · CIP-001WM

Primary sources (government registries)

ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗